Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1994-01-24
1997-04-29
Knode, Marian C.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 79, 435 792, 436 63, 436518, 436547, 436548, 436811, G01N 33573, G01N 3353, G01N 3348
Patent
active
056248075
ABSTRACT:
Methods for screening individuals for Alzheimer's disease are disclosed. Also disclosed are antibodies that immunochemically react with the isoforms of calcium-activated neutral proteinases which are characteristic of Alzheimer's disease. Also disclosed are methods for screening drugs which are useful in treating or preventing Alzheimer's disease.
REFERENCES:
patent: 5134062 (1992-07-01), Blass
Winkler, "Tacrine for Alzheimer's Disease", JAMA, 271(13):1023-1024 (Apr. 6, 1994).
Morris et al, "The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)", Neurology:39:1159-1165 (Sep. 1989).
Marotta, Charles, A., "Molecular Biology of Neuronal Aging", Department of Health and Human Services Grant Application, executed Jun. 1986, funded before 1990.
Nixon, Ralph, A., "Proteolysis in Normal and Pathological Axons and Glia", Department of Health and Human Services Grant Application, executed Jun. 1982, funded before 1990.
Nixon, Ralph, A., "Human Brain Proteolysis in Aging and Alzheimer's Disease", Department of Health and Human Services Grant Application, executed Sep. 1983, funded before 1990.
Nixon, Ralph, A., "Human Brain Proteolysis in Aging and Alzheimer's Disease", Department of Health and Human Services Grant Application, executed Oct. 1986, funded before 1990.
Perlmutter et al., "Distribution of calcium-activated protease calpain in the rat brain", J. Comp. Neurol. 296:269-276 (1990).
Saito et al., "Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration", Proc. Natl. Acad. Sci. USA 90:2628-2632 (Apr. 1993).
Adunsky et al., Increased cytosolic free calcium in Lymphocytes of Alzheimer patients, Journal of Neuroimmunology 33:167-172 (1991).
Colvin et al., Na+/Ca2+ exchange activity is increased in Alzheimer's disease brain tissues, Brain Research 543:139-147 (1991).
Dure et al., Excitatory Amino Acid Binding Sites in the Caudate Nucleus and Frontal Cortex of Huntington's Disease, Annals of Neurology 30(6):785-793 (Dec. 1991).
Elce et al., Calpain I activation is not correlated with aggregation in human platelets, Biochem. J. 261:1039-1042 (1989).
Ham et al., Development of Improved Media and Culture Conditions for Clonal Growth of Normal Diploid Cells, In Vitro 14(1):11-22 (1978).
Imajoh et al., Molecular Cloning of the cDNA for the Large Subunit of the High-Ca2+-Requiring Form of Human Ca2+-Activated Neutral Protease, Biochemistry 27:8122-8128 (1988).
Inomata et al., Autolytic Activation of Calcium-Activated Neutral Protease, Biochemical and Biophysical Research Communications 138(2):638-643 (Jul. 31, 1986).
Inomata et al., Purification and Characterization of a Calcium-Activated Neutral Protease from Rabbit Skeletal Muscle which Requires Calcium Ions of .mu.M Order . . . , J. Biochem. 93:291-294 (1983).
Inomata et al., Properties of Erythrocyte Membrane Binding and Autolytic Activation of Calcium-activated Neutral Protease, Journal of Biological Chemistry 264(31):18838-18843 (1989).
Iwamoto et al., Localization of calpain immunoreactivity in senile plaques and in neurones undergoing neurofibrillary degeneration in Alzheimer's disease, Brain Research 561:177-180 (1991).
Joachim et al., Amyloid Beta-Protein Deposition in Tissues other than Brain in Alzheimer's Disease, Nature 341:226-230 (Sep. 21, 1989).
Kawashima et al. Transglutaminase and Calcium-Protease Activities in Alzheimer's Disease Brain, Biomedical Research 10(1):17-23 (1989).
Mantle et al., Comparison of Ca2+-activated proteinase enzyme and endogeneous inhibitor activity in brain tissue from normal and Alzheimer's disease cases, J. Neurol. Sci. 102:220-224 (1991).
Murachi, T., Intracellular Regulatory System Involving Calpain and Calpastatin, Biochemistry International 18(2):263-294 (Feb. 1989).
Nee et al., A Family with Histologically Confirmed Alzheimer's Disease, Arch. Neurol. 40:203-208 (Apr. 1983).
Nilsson et al., Calpain and Calpastatin in Normal and Alzheimer-Degenerated Human Brain Tissue, Neurobiology of Aging 11:425-431 (1990).
Nixon, R.A., Calcium-Activated Neutral Proteinases as Regulators of Cellular Function, Implications for Alzheimer's Disease Pathogenesis, Annals New York Academy of Sciences 568:198-208 (1989).
O'Brien et al., Protease Inhibitors Reduce the Loss of Nerve Terminals Induced by Activity and Calcium in Developing Rat Soleus Muscles In Vitro, Neuroscience 12(2):637-646 (1984).
Perlmutter et al., The Ultrastructural Localization of Calcium-Activated Protease "Calpain" in rat brain Synapse 2:79-88 (1988).
Peterson et al., Altered Calcium Uptake in Cultured Skin Fibroblasts From Patients With Alzheimer's Disease, New England Journal of Medicine 312 (16):1063-1064 (Apr. 18, 1985).
Peterson et al., Increased spectrin proteolysis in fibroblasts from aged and Alzheimer donors, Neuroscience Letters 121:239-343 (1991).
Pontremoli et al., Activation by Hemoglobin of the Ca2+-Requiring Neutral Proteinase of Human Erythrocytes: Structural Requirements, Biochem. and Biophys. Res. Comm. 123(1):331-337 (Aug. 30, 1984).
Saido et al., Autolytic Transition of .mu.-Calpain upon Activation as Resolved by Antibodies Distinguishing between the Pre-and Post-Autolysis Forms, J. Biochem. 111:81-86 (1992).
Saido et al., Proteolysis of Protein Kinase C by Calpain: Effects of Acidic Phospholipids, Biomed. Biochim. Acta 50:485-489 (1991).
Saitoh et al., Biology of Disease, Protein Kinases and Phosphorylation in Neurologic Disorders and Cell Death, Laboratory Investigation 64(5):596-616 (1991).
Samis et al., Calpain I remains intact and intracellular during platelet activation, Biochem. J. 246:481-488 (1987).
Sevier et al., Monoclonal Antibodies in Clinical Immunology, Clin. Chem. 27/11:1797-1806 (1981).
Siman et al., Proteolytic Processing of .beta.-Amyloid Precursor by Calpain I, Journal of Neuroscience 10(7):2400-2411 (Jul. 1990).
Siman, R., Role of Calpain I in Excitatory Amino Acid-Induced Degenerative Structural Changes, Neurotox. of Excitatory Amino Acids, Guidotti, A., ed., Raven Press, Ltd., New York, pp. 145-161 (1990).
Swanson et al., Effects of low calcium and inhibition of calcium-activated neutral protease (CANP) on mature nerve terminal structure in the rat sternocostalis muscle, Dev. Br. Res. 33:199-203 (1987).
Takeuchi et al., Immunoassay and Activity of Calcium-Activated Neutral Proteinase (mCANP): Distribution in Soluble and Membrane-Associated Fractions in . . . , J. Neurochem. 58(4):1526-1532 (1992).
Tanzi et al., Amyloid Beta Protein Gene: cDNA, mRNA distribution, and Genetic Linkage near the Alzheimer's Locus, Science 235:880-884 (Feb. 20, 1987).
Tanzi et al., Protease Inhibitor Domain Encoded by an Amyloid Protein Precursor mRNA Associated with Alzheimer's Disease, Nature 331:528-530(Feb. 11, 1988).
Tanzi et al., The Genetic Defect in Familial Alzheimer's Disease is not Tightly Linked to the Amyloid Beta-Protein Gene, Nature 329:156-157 (Sep. 10, 1987).
Vitto et al., Calcium-Activated Neutral Proteinase of Human Brain: Subunit Structure and Enzymatic Properties of Multiple Molecular Forms, Journal of Neurochemistry 47(4):1039-1051 (1986).
Willers et al., Growth Studies on Fibroblasts of Patients with Autosomal Recessive Friedreich's Ataxia, Pathobiology 59:357-360 (1991).
Zimmerman et al., Two-stage autolysis of the catalytic subunit initiates activation of Calpain I, Biochimica et Biophysica Acta 1078:192-198 (1991) .
Nixon Ralph A.
Saito Ken-Ichi
Duffy Patricia A.
Knode Marian C.
The McLean Hospital Corporation
LandOfFree
Methods for detecting Alzheimer's disease by measuring ratios of does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for detecting Alzheimer's disease by measuring ratios of, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for detecting Alzheimer's disease by measuring ratios of will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-704889